Email updates

Keep up to date with the latest news and content from JTM and BioMed Central.

Open Access Highly Accessed Review

Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis

Neil H Riordan1, Thomas E Ichim1*, Wei-Ping Min2, Hao Wang2, Fabio Solano3, Fabian Lara3, Miguel Alfaro4, Jorge Paz Rodriguez5, Robert J Harman6, Amit N Patel7, Michael P Murphy8, Roland R Lee109 and Boris Minev1112

Author Affiliations

1 Medistem Inc, San Diego, CA, USA

2 Department of Surgery, University of Western Ontario, London, Ontario, Canada

3 Cell Medicine Institutes, San Jose, Costa Rica

4 Hospital CIMA, San Jose, Costa Rica

5 Cell Medicine Institutes, Panama City, Panama

6 Vet-Stem, Inc. Poway, CA, USA

7 Dept of Cardiothoracic Surgery, University of Utah, Salt Lake City, Utah, USA

8 Division of Medicine, Indiana University School of Medicine, Indiana, USA

9 Department of Radiology, University of Canlfornia San Diego, San Diego, CA, USA

10 Veterans Administration, San Diego, CA, USA

11 Moores Cancer Center, University of California, San Diego, CA, USA

12 Department of Medicine, Division of Neurosurgery, University of California San Diego, San Diego, CA, USA

For all author emails, please log on.

Journal of Translational Medicine 2009, 7:29  doi:10.1186/1479-5876-7-29

Published: 24 April 2009

Abstract

The stromal vascular fraction (SVF) of adipose tissue is known to contain mesenchymal stem cells (MSC), T regulatory cells, endothelial precursor cells, preadipocytes, as well as anti-inflammatory M2 macrophages. Safety of autologous adipose tissue implantation is supported by extensive use of this procedure in cosmetic surgery, as well as by ongoing studies using in vitro expanded adipose derived MSC. Equine and canine studies demonstrating anti-inflammatory and regenerative effects of non-expanded SVF cells have yielded promising results. Although non-expanded SVF cells have been used successfully in accelerating healing of Crohn's fistulas, to our knowledge clinical use of these cells for systemic immune modulation has not been reported. In this communication we discuss the rationale for use of autologous SVF in treatment of multiple sclerosis and describe our experiences with three patients. Based on this rationale and initial experiences, we propose controlled trials of autologous SVF in various inflammatory conditions.